“Our data strongly suggest that KIF1Bβ, which is localized on chromosome 1p36, might be such a neuroblastoma tumor suppressor gene,” says principal investigator Susanne Schlisio at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet and Assistant Member at the Ludwig Institute for Cancer Research in Stockholm, Sweden.
Neuroblastoma tumors originate from the same transient progenitor cells — neural crest cells — that give rise to the nervous system along with other tissues. Members of some families are at higher risk than others to develop tumors that originate from these cells due to mutations in specific genes. The research team behind the new study previously discovered that genes mutated in some of the tumors play a central role in determining whether neural crest cells live or die. Neural crest cells that should ordinarily have succumbed to programmed cell death escape that fate when KIF1B-β is lost. Later in life, the cells might develop into cancer cells.
In the current study, the investigators describe the mechanisms by which KIF1B-β causes cell death. They found that KIF1B-β affects the cells´ power stations, the mitochondria, by activating an enzyme named calcineurin. Schlisio and her colleagues also show that a critical signal required to induce cell death by fragmenting the mitochondria is compromised by the loss of KIF1B-β. By examining neuroblastoma tumors biopsied from patients, the researchers demonstrate that loss of KIF1B-β is associated with poor prognosis and reduced survival.
The team also demonstrates a general mechanism that can explain how calcium-dependent signalling by calcineurin is executed. This is a significant finding because the loss of control of calcineurin signalling seems to play a role in many diseases, including neurodegenerative disease, cardiac disease and cancers.
“We conclude that KIF1B-β plays a key role in the decision between life and death for neural crest cells and tumors originating from the neural crest,” says Susanne Schlisio. “In time, knowledge of the mechanism by which KIF1B-β induce cell death might prove important in attempts to develop new neuroblastoma therapies.”